| Literature DB >> 35144658 |
Pauline Bayerle1, Arno Kerling2, Sven Haufe2, Lars Nachbar3, Momme Kück2, Simone Rolff2, Hedwig Theda Boeck2, Thorben Sundermeier2, Ralf Ensslen3, Uwe Tegtbur2, Dirk Lauenstein4, Dietmar Böthig5, Christoph Bara5, Alexander Hanke2, Christoph Terkamp6, Axel Haverich5, Meike Stiesch7, Martina de Zwaan8.
Abstract
BACKGROUND: Metabolic syndrome (MetS) is associated with an increased risk for cardiovascular events and high socioeconomic costs. Despite lifestyle interventions focusing on exercise are effective strategies to improve parameters of the above aspects, many programs fail to show sustained effects in the long-term.Entities:
Keywords: Company employees; Maintenance; Metabolic syndrome; Physical activity; Sustainability; Telemonitoring; Wearable device; Work ability
Year: 2022 PMID: 35144658 PMCID: PMC8829995 DOI: 10.1186/s13102-022-00409-1
Source DB: PubMed Journal: BMC Sports Sci Med Rehabil ISSN: 2052-1847
Fig. 1Study design
Fig. 2Allocation of participants at maintenance treatment phase including dropouts
Subject characteristics at visit 2
| Parameter | A | B | C | p-value |
|---|---|---|---|---|
| Female / male | 5 / 38 | 8 / 35 | 6 / 37 | 0.649 |
| Age (yrs) | 50.3 ± 7.2 | 47.9 ± 8.2 | 47.6 ± 7.5 | 0.194 |
| Body weight (kg) | 102.8 ± 19.0 | 99.7 ± 15.9 | 99.8 ± 16.8 | 0.638 |
| Body mass index (kg/m2) | 32.0 ± 5.4 | 31.4 ± 4.7 | 31.3 ± 4.5 | 0.742 |
| Waist circumference (cm) | ||||
| Female | 106.6 ± 8.3 | 107.6 ± 11.0 | 102.7 ± 8.2 | 0.623 |
| Male | 111.1 ± 13.1 | 107.9 ± 12.2 | 108.3 ± 12.4 | 0.481 |
| Fasting glucose concentration (mg/dl) | 111.3 ± 35.8 | 99.1 ± 15.7 | 102.9 ± 17.5 | 0.071 |
| Triglyceride (mg/dl) | 180.6 ± 207.8 | 153.3 ± 94.9 | 191.8 ± 140.0 | 0.491 |
| HDL (mg/dl) | 44.5 ± 8.9 | 47.5 ± 8.6 | 43.5 ± 9.5 | 0.111 |
| Resting RRsys (mmHg) | 129.9 ± 10.1 | 129.5 ± 11.8 | 133.2 ± 11.3 | 0.140 |
| MetS-z-score | 0.75 ± 0.85 | 0.47 ± 0.64 | 0.72 ± 0.71 | 0.232 |
Subgroup A—wearables and personal consultation, Subgroup B—wearables only, Subgroup C—no technical or personal support
HDL high density lipoprotein
Fig. 3a–d Relative exercise capacity (a), total PA (b), WAItotal (c) and MetS-z-score (d) in the whole intervention group across baseline, visit 2 and visit 3, and in the subgroups A, B and C across the maintenance phase from visit 2 to visit 3. Relative exercise capacity (p < 0.001, η2 = 0.46), total PA (p < 0.001, η2 = 0.24) and WAItotal (p < 0.001, η2 = 0.18) increased significantly across the three time points, respectively decreased for MetS-z-score (p < 0.001, η2 = 0.23). WAI work ability index, PA physical activity
Change after 6 months maintenance treatment phase
| A | B | C | Time | Time × group | |||||
|---|---|---|---|---|---|---|---|---|---|
| Visit 2 | Visit 3 | Visit 2 | Visit 3 | Visit 2 | Visit 3 | p-value | p-value | η2 | |
| Body weight (kg) | 102.8 ± 19.0 | 103.9 ± 19.4* | 99.7 ± 15.9 | 99.5 ± 16.6 | 99.8 ± 16.8 | 100.3 ± 17.8 | 0.116 | 0.148 | 0.03 |
| Body mass index (kg/m2) | 32.0 ± 5.4 | 32.4 ± 5.6* | 31.4 ± 4.7 | 31.4 ± 5.0 | 31.3 ± 4.5 | 31.4 ± 4.8 | 0.122 | 0.157 | 0.03 |
| Fat mass (kg) | 31.7 ± 13.5 | 32.9 ± 13.4* | 30.5 ± 11.5 | 30.5 ± 12.7 | 30.5 ± 12.3 | 30.6 ± 12.8 | 0.143 | 0.299 | 0.02 |
| Fat-free mass (kg) | 71.3 ± 9.7 | 71.0 ± 10.1 | 69.1 ± 12.4 | 69.3 ± 13.0 | 69.4 ± 10.3 | 69.7 ± 11.0 | 0.862 | 0.652 | 0.01 |
| Body fat (%) | 29.7 ± 8.6 | 30.7 ± 8.3* | 30.2 ± 9.7 | 30.2 ± 10.3 | 30.0 ± 8.6 | 29.8 ± 9.0 | 0.341 | 0.110 | 0.03 |
| Waist circumference (cm) | 110.6 ± 12.6 | 112.0 ± 13.9 | 107.8 ± 11.9 | 107.6 ± 12.8 | 107.5 ± 12.0 | 109.0 ± 12.5* | 0.042 | 0.176 | 0.03 |
| Glucose (mg/dl) | 111.3 ± 35.8 | 110.8 ± 30.3 | 99.1 ± 15.7 | 99.4 ± 16.5 | 102.9 ± 17.5 | 100.7 ± 13.3 | 0.560 | 0.745 | 0.00 |
| Triglyzeride (mg/dl) | 180.6 ± 207.8 | 189.1 ± 218.2 | 153.3 ± 94.9 | 140.3 ± 80.5 | 191.8 ± 140.0 | 187.7 ± 131.9 | 0.630 | 0.341 | 0.02 |
| HDL (mg/dl) | 44.5 ± 8.9 | 44.7 ± 9.9 | 47.5 ± 8.6 | 46.4 ± 10.0 | 43.5 ± 9.5 | 43.0 ± 8.7 | 0.299 | 0.532 | 0.01 |
| RRsys (mmHg) | 129.9 ± 10.1 | 134.1 ± 12.5* | 129.5 ± 11.8 | 129.7 ± 11.0 | 133.2 ± 11.3 | 134.8 ± 14.6 | 0.042 | 0.256 | 0.02 |
| RRdia (mmHg) | 83.2 ± 8.7 | 86.3 ± 9.9*a | 84.7 ± 9.2 | 82.5 ± 7.1a | 85.5 ± 6.8 | 86.3 ± 9.1 | 0.405 | 0.006 | 0.08 |
| MetS-z-score | 0.75 ± 0.85 | 0.78 ± 0.93 | 0.47 ± 0.64 | 0.42 ± 0.66 | 0.72 ± 0.71 | 0.72 ± 0.64 | 0.862 | 0.676 | 0.01 |
| Peak exercise capacity (W) | 193.5 ± 35.4 | 192.1 ± 36.4 | 197.7 ± 45.9 | 203.0 ± 51.8* | 198.8 ± 32.9 | 197.9 ± 35.8 | 0.532 | 0.164 | 0.03 |
| Relative exercise capacity (W/kgBW) | 1.93 ± 0.44 | 1.90 ± 0.45 | 2.02 ± 0.53 | 2.08 ± 0.60* | 2.02 ± 0.34 | 2.00 ± 0.36 | 0.790 | 0.068 | 0.04 |
Subgroup A—wearables and personal consultation, Subgroup B—wearables only, Subgroup C—no technical or personal support
HDL high density lipoprotein; BW body weight
*p < 0.05 visit 2 versus visit 3
ap < 0.01 post hoc time × group effect A versus B
Change in outcomes by questionnaires after 6 months maintenance treatment phase
| A | B | C | Time | Time × group | |||||
|---|---|---|---|---|---|---|---|---|---|
| visit 2 | visit 3 | visit 2 | visit 3 | visit 2 | visit 3 | p-value | p-value | η2 | |
| WAItotal | 38.3 ± 4.8 | 37.7 ± 6.0 | 40.2 ± 4.1 | 40.2 ± 6.2 | 40.3 ± 5.0 | 39.1 ± 5.7* | 0.115 | 0.387 | 0.01 |
| Everyday activity (MET*h/week) | 32.0 ± 24.0 | 25.6 ± 16.8 | 34.3 ± 23.8 | 23.7 ± 19.7* | 33.5 ± 23.6 | 25.5 ± 19.3* | < 0.001 | 0.675 | 0.01 |
| Exercise activity (MET*h/week) | 16.0 ± 16.7 | 11.5 ± 11.7 | 18.3 ± 27.0 | 20.1 ± 36.1 | 18.0 ± 17.1 | 11.4 ± 9.8* | 0.105 | 0.178 | 0.03 |
| Total PA (MET*h/week) | 48.0 ± 33.6 | 37.1 ± 23.0* | 52.6 ± 35.7 | 43.8 ± 40.7* | 51.5 ± 29.7 | 36.9 ± 22.8* | < 0.001 | 0.685 | 0.01 |
| Anxiety severity (HADS-D) | 3.67 ± 2.40 | 4.30 ± 3.20 | 4.31 ± 3.14 | 4.19 ± 3.64 | 3.70 ± 3.35 | 3.88 ± 4.29 | 0.319 | 0.419 | 0.01 |
| Depression severity (HADS-D) | 2.77 ± 2.52 | 3.33 ± 3.08 | 3.33 ± 3.10 | 2.98 ± 3.02 | 2.33 ± 2.51 | 2.98 ± 3.27* | 0.140 | 0.064 | 0.04 |
| Physical component score (SF-36) | 49.6 ± 7.9 | 50.0 ± 8.6 | 50.8 ± 7.6 | 51.4 ± 9.7 | 51.7 ± 6.2 | 51.9 ± 5.6 | 0.467 | 0.957 | 0.00 |
| Mental component score (SF-36) | 54.0 ± 5.5 | 54.0 ± 5.5 | 52.2 ± 9.1 | 52.2 ± 9.1 | 53.9 ± 6.9 | 53.8 ± 6.9 | 0.382 | 0.394 | 0.01 |
Subgroup A—wearables and personal consultation, Subgroup B—wearables only, Subgroup C—no technical or personal support
WAI work ability index, PA physical activity
*p < 0.05 visit 2 vs visit 3
Comparison of exercise parameters of the initial intervention and maintenance treatment phase
| A | B | Time | Time × group | |||||
|---|---|---|---|---|---|---|---|---|
| Initial intervention | Maintenance treatment | Initial intervention | Maintenance treatment | p-value | η2 | p-value | η2 | |
| Total exercise units | 73.8 ± 68.3* | 60.0 ± 62.0* | 84.5 ± 74.5* | 64.6 ± 57.9* | < 0.001 | 0.15 | 0.499 | 0.01 |
| Exercise units per week | 2.84 ± 2.63* | 2.31 ± 2.38* | 3.25 ± 2.87* | 2.49 ± 2.23* | < 0.001 | 0.15 | 0.499 | 0.01 |
| PA per week (min) | 113.3 ± 105.6 | 115.6 ± 169.5 | 127.9 ± 101.2* | 103.0 ± 88.8* | 0.407 | 0.01 | 0.320 | 0.01 |
| Daily step count | 8235 ± 3590* | 6876 ± 4106* | 7429 ± 3091* | 5950 ± 3774* | < 0.001 | 0.21 | 0.848 | < 0.01 |
| Heart rate (bpm) | 116.8 ± 12.6 | 116.1 ± 12.0 | 114.6 ± 8.6 | 115.3 ± 10.4 | 0.977 | 0.00 | 0.272 | 0.02 |
| Adherence goal fulfilled (weeks) | 7.05 ± 7.01 | 6.28 ± 7.29 | 8.17 ± 7.07* | 6.31 ± 6.73* | 0.014 | 0.07 | 0.303 | 0.01 |
| Wear time per week (%) | 83.5 ± 17.0* | 67.1 ± 28.0* | 82.9 ± 12.5* | 61.9 ± 29.6* | < 0.001 | 0.31 | 0.524 | 0.01 |
*p < 0.05 initial intervention vs maintenance treatment